



## **Pragma Pharmaceuticals Announces Re-Launch of Moxatag®**

NEW YORK— August 14, 2014-- Pragma Pharmaceuticals is pleased to announce that it is re-launching Moxatag® 775 mg (amoxicillin extended-release tablets), the only once-a-day amoxicillin.

Pragma acquired Moxatag from Shionogi Inc. in March 2014 and has been working to make the product available in time for the upcoming cold and flu season.

A Pragma spokesperson says, “Amoxicillin is the gold standard in treating strep pharyngitis. Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy.”

Fera Pharmaceuticals has been selected to manage the sales and marketing of Moxatag for Pragma.

### About Moxatag

Moxatag, the first and only once-a-day amoxicillin, is indicated for the treatment of tonsillitis and/or pharyngitis secondary to *Streptococcus pyogenes* (*S. pyogenes*) in adult and pediatric patients 12 years of age or older. For more information visit [www.moxatag.com](http://www.moxatag.com)

### Contact:

Louis B. DellaFera, Pharm. D.  
516-209-5978  
[Louis@pragmapharma.com](mailto:Louis@pragmapharma.com)